Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Parmveer Singh
Observed name:
Singh, Parmveer
Institution:
Opna Bio (United States)
Observed institutions:
University of Alberta,
University of Toronto,
Plexxikon (United States),
Opna Bio (United States),
Newcastle University
ORCID:
0000-0002-9956-0272
Observed ORCID:
0000-0002-9956-0272
OpenAlex ID:
A5071297735
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model
2019
·
Elizabeth Spangenberg
, Paul L. Severson
, et al.
·
Nature Communications
·
990
PDF
Reactive microglia are the major source of tumor necrosis factor alpha and contribute to astrocyte dysfunction and acute seizures in experimental temporal lobe epilepsy
2022
·
Lukas Henning
, Henrike Antony
, et al.
·
Glia
·
73
PDF
Propagation of human prostate tissue from induced pluripotent stem cells
2020
·
Anastasia C. Hepburn
, Emma L. Curry
, et al.
·
Stem Cells Translational Medicine
·
37
PDF
Genetic backgrounds and modifier genes of NTD mouse models: An opportunity for greater understanding of the multifactorial etiology of neural tube defects
2016
·
Renee Y.M. Leduc
, Parmveer Singh
, et al.
·
Birth Defects Research
·
35
A Review of Prostate Organogenesis and a Role for iPSC-Derived Prostate Organoids to Study Prostate Development and Disease
2021
·
Adriana Buskin
, Parmveer Singh
, et al.
·
International Journal of Molecular Sciences
·
26
PDF
Contrasting Patterns in the Evolution of Vertebrate MLX Interacting Protein (MLXIP) and MLX Interacting Protein-Like (MLXIPL) Genes
2016
·
Parmveer Singh
, David M. Irwin
·
PLoS ONE
·
15
PDF
Human prostate organoid generation and the identification of prostate development drivers using inductive rodent tissues
2023
·
Parmveer Singh
, Nadia A. Lanman
, et al.
·
Development
·
9
PDF
Abstract 660: OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
2024
·
Bernice Matusow
, Wayne Spevak
, et al.
·
Cancer Research
·
2
OPN-6602, an Orally Bioavailable EP300/CBP Bromodomain Inhibitor, Targets Multiple Myeloma through Suppression of IRF4 and MYC
2024
·
Bernice Matusow
, Sadegh Saghafinia
, et al.
·
Blood
·
1
A Phase 1b, Dose Escalation/Dose Expansion, Multicenter, Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma
2024
·
Jackie M. Walling
, Bernice Matusow
, et al.
·
Blood
·
1
PDF
Abstract C085: OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription, including MYC, in mCRPC
2023
·
Bernice Matusow
, Wayne Spevak
, et al.
·
Molecular Cancer Therapeutics
·
1
Analysis of variants of Dnmbp, a Putative Modifier of Cecr2 and Neural Tube Defect Susceptibility Gene
2017
·
Singh, Parmveer
·
ERA: Education and Research Archive (University of Alberta)
Show more works
View as search
Works count:
12
Citation count:
1,186
H-index:
7
I10-index:
6
Year
Topic
Type